Targeting ACLY efficiently inhibits SARS-CoV-2 replication

靶向 ACLY 可有效抑制 SARS-CoV-2 复制

阅读:8
作者:Terrence Tsz-Tai Yuen, Jasper Fuk-Woo Chan, Bingpeng Yan, Cynthia Cheuk-Ying Shum, Yuanchen Liu, Huiping Shuai, Yuxin Hou, Xiner Huang, Bingjie Hu, Yue Chai, Chaemin Yoon, Tianrenzheng Zhu, Huan Liu, Jialu Shi, Jinjin Zhang, Jian-Piao Cai, Anna Jinxia Zhang, Jie Zhou, Feifei Yin, Shuofeng Yuan, Bao-

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the biggest public health challenge the world has witnessed in the past decades. SARS-CoV-2 undergoes constant mutations and new variants of concerns (VOCs) with altered transmissibility, virulence, and/or susceptibility to vaccines and therapeutics continue to emerge. Detailed analysis of host factors involved in virus replication may help to identify novel treatment targets. In this study, we dissected the metabolome derived from COVID-19 patients to identify key host factors that are required for efficient SARS-CoV-2 replication. Through a series of metabolomic analyses, in vitro, and in vivo investigations, we identified ATP citrate lyase (ACLY) as a novel host factor required for efficient replication of SARS-CoV-2 wild-type and variants, including Omicron. ACLY should be further explored as a novel intervention target for COVID-19.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。